key: cord-0746250-xc6h14yu
authors: Gupta, Akshita; Soni, Anushika; Rooge, Sheetalnath; Paul, Diptanu; Agarwal, Reshu; Tarai, Bansidhar; Gupta, Ekta
title: Syndromic approach to SARS-CoV-2 detection using QIAstat-Dx SARS-CoV-2 Panel from clinical samples
date: 2021-09-22
journal: J Virol Methods
DOI: 10.1016/j.jviromet.2021.114300
sha: f935632ceebc16ef7fc2a1457edecd8268f4e774
doc_id: 746250
cord_uid: xc6h14yu

The QIAstat-Dx SARS-CoV-2 panel is a multiplex cartridge based assay based on real time PCR which can detect 17 respiratory viruses, including the novel coronavirus SARS-CoV-2. A syndromic approach is the need of the hour for COVID-19 diagnostics among patients presenting with respiratory symptoms. The present study was done to evaluate 120 archived respiratory clinical specimens for SARS-CoV-2 on the SARS-CoV-2 panel. Further, 27 specimens were tested for other respiratory viruses, in comparison with the BioFire RP1.7 platform. The sensitivity and specificity for SARS-CoV-2 on SARS panel was found to be 90.00% and 100% respectively, indicating good diagnostic accuracy. The positive predictive value was found to be 100%, negative predictive value was found to be 99.93% and accuracy was 99.93%. Detection of other respiratory viruses observed a concordance of 77.7%. Despite advantages of speed, minimal expertise and accurate results; significant costs and discrepancies at Ct >35 remain important limitations of the SARS panel.

The introduction of multiplex, point-of-care tests (POC) for severe acute respiratory syndrome 

A retrospective study was conducted over 2 months on archived respiratory specimens (throat and nasopharyngeal swabs, NPS) from 1 November 2020 to 31 December 2020. The study was approved by Institutional Ethics committee and performed as per the Helsinki code. All clinical information were obtained from the hospital information system (HIS).

The study was done on archived samples kept at -80 °C in the Department repository. The study involved a total of 147 samples that were randomly selected from the database. Group 1 included 120 samples which were selected as per the SARS-CoV-2 RT-PCR results (60 J o u r n a l P r e -p r o o f positive and 60 negative) and they all were negative for any other respiratory virus, group 2 included 27 samples that were all negative for SARS-CoV-2 but positive for other respiratory viruses. (Figure 1 ) This division was done to evaluate the QIAstat-Dx assay across all the respiratory viral pathogens. All the retrieved samples were tested, in a single freeze thaw cycle, in parallel on QIAstat-Dx and re tested on both RealStar RT-PCR as well as the Biofire FilmArray RP1.7 to reconfirm the earlier lab results. 

We evaluated a total of 147 specimens on the SARS-CoV-2 Panel. The median age of the study group was 38 (IQR:15 -68) years with Male: Female ratio was 3.1:1. to 96.24%) the specificity was found to be 100% (95% CI:94.04% to 100.00%). (Table 1) Overall agreement of SARS-CoV-2 Panel with RT PCR was 95.0%. There were 6 discordant samples which were positive on RealStar RT-PCR but negative on SARS-CoV-2 Panel. These discrepant cases were retested on RealStar RT-PCR and it was seen that there was amplification in both the genes but with higher C T values (>35).

The performance of the assay was further evaluated and correlation was assessed. Pearson's correlation coefficient was found to be 0.93 and R 2 coefficient of determination was found to 

The arrival of POC tests for SARS-CoV-2 diagnostics are game changing when deciding triaging, isolation implementation and therapy of patients. [2] The SARS-CoV-2 Panel provides a novel sensitive and specific method to diagnose multiple viral infections in at risk patients in the midst of a pandemic. Delay in reporting due to centralised laboratory PCR testing is a significant challenge and SARS-CoV-2 Panel represents an important step to improve detection potential co-infections or superinfections. [5, 6] Our study found good performance characteristics, similar to other published studies on the QIAstat-Dx, where a positive percent agreement and negative percent agreement with RT-PCR as the reference standard was more than 90%. [4, 7] Further, correlation between the C T values on the RealStar and QIAstat-Dx platforms were observed. We observed discrepant results on SARS-CoV-2 Panel in 6 cases with C T values >35 on the Qiastat-Dx. The higher C T values of these cases may indicate presence of degraded viral RNA and viral clearance or possible false positive on RT PCR. [8] Now even Indian council of medical research (ICMR) has stated in their guidelines that samples on RT-PCR should be given positive only with Ct values < 35. [9] However, earlier all amplifications in both the genes even if > 35 Ct value were considered as positive while reporting. The SARS-CoV-2 Panel was also evaluated for detection of respiratory viruses other than SARS-CoV-2 using the BioFire RP1.7 as the reference standard. Concordance was found to be 77.7% between both platforms. This could be due to different primer targets for various viruses on BioFire RP1.7 and SARS-CoV-2 Panel. Thus, a larger prospective study is required to assess the sensitivity of these platforms in the Indian setting. Sensitivity for detection of Human Rhinovirus/Enterovirus and coronavirus 229E on the SARS-CoV-2 Panel appears to In conclusion, performance and costs of implementation need to be further evaluated with a larger number of subjects before application in routine investigations in India. Furthermore, evaluation of this point-of-care test in critical care settings is desirable as SARS-CoV-2 becomes a regular differential among respiratory viral infections. 

Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19

Multicenter Evaluation of QIAstat-Dx Respiratory Panel V2 for Detection of Viral and Bacterial Respiratory Pathogens. Carroll KC, editor

Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection

Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit? Front Public Health

Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study

Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel

The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2

Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients

Coronavirus 229E Coronavirus 229E Yes 10 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 11 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 12 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 13 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 14 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 15 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 16 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 17 Human Rhinovirus/Enterovirus TND No 18 Human Rhinovirus/Enterovirus TND No 19 Coronavirus 229E Coronavirus 229E Yes 20 Human Rhinovirus/Enterovirus Human Rhinovirus/Enterovirus Yes 21

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.